Celtaxsys Revenue and Competitors
Estimated Revenue & Valuation
- Celtaxsys's estimated annual revenue is currently $2.8M per year. 0
- Celtaxsys's total funding is $65.2M.
Employee Data
- 00
Celtaxsys Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $24.5M | 122 | 8% | N/A | N/A |
#2 | $10.7M | 53 | -17% | N/A | N/A |
#3 | $9.2M | 46 | 2% | N/A | N/A |
#4 | $24.1M | 120 | 5% | N/A | N/A |
#5 | $7.2M | 36 | -20% | N/A | N/A |
#6 | $27.7M | 138 | -30% | N/A | N/A |
#7 | $39.8M | 198 | 37% | N/A | N/A |
#8 | $0.5M | 5 | 25% | $50M | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $10.3M | 51 | 11% | N/A | N/A |
What Is Celtaxsys?
Celtaxsys was founded in 2005 with a focus on chemokine-mediated immune cell migration. Originally organized around technology licensed from the Massachusetts General Hospital and Harvard Medical School, Celtaxsys has grown beyond this license to develop a unique discovery platform that has identified and characterized novel mechanisms of immune cell migration that are unrelated to chemokines themselves. Celtaxsys is defining new biology in the area of immune cell chemotaxis.
keywords:N/A
$65.2M
Total Funding
N/A
Number of Employees
$2.8M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Celtaxsys News
2022-04-20 - Blood Pressure Disorders Drug Market Major Technology ...
... Camurus AB, Capricor Therapeutics Inc, Celsion Corp, Celtaxsys Inc, Chiesi Farmaceutici SpA, Chong Kun Dang Pharmaceutical Corp,...
Other Companies in Atlanta
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.1M | 0 | N/A | $52M |
#2 | $6.3M | 0 | N/A | $31M |
#3 | $5.1M | 0 | N/A | N/A |
#4 | $100.1M | 0 | N/A | N/A |
#5 | $5.2M | 0 | N/A | $3M |